IPF Serum Biomarkers: KL-6, SP-D, MMP-7, CCL-18 Guide
A practical guide to IPF serum biomarkers KL-6, SP-D, MMP-7, and CCL-18—biological rationale, clinical data, cutoffs, and preclinical measurement.
Introduction: FVC Alone Is Not Enough — The Promise of Serum Biomarkers
Assessment of treatment efficacy in Idiopathic Pulmonary Fibrosis (IPF) has historically relied heavily on changes in Forced Vital Capacity (FVC). However, FVC measurements have significant variability, and detecting meaningful differences in short-term clinical trials is challenging. Because FVC decline reflects irreversible structural changes, there is a growing clinical and drug-development need to "capture treatment effects at an earlier stage."
Against this backdrop, serum biomarkers are gaining attention as tools for IPF diagnosis support, prognosis prediction, and treatment monitoring. This article provides a practical overview of four biomarkers with accumulated clinical evidence—KL-6, SP-D, MMP-7, and CCL-18—covering biological rationale through preclinical measurement.
For broader context on biomarkers and fibrosis markers from other organs, please also refer to the Comprehensive Guide to Fibrosis Biomarkers.
1. KL-6 (Krebs von den Lungen-6)
Biological Background
KL-6 is a high-molecular-weight mucin-like glycoprotein (a sialylated epitope of MUC1) expressed on the surface of type II alveolar epithelial cells. Its expression is upregulated during repeated cycles of alveolar epithelial injury and regeneration, and it leaks into the bloodstream as alveolar barrier integrity is compromised.
Clinical Data
- In Japan, KL-6 has been covered by health insurance since 2000, and is widely used for ILD screening and activity assessment.
- In Japanese clinical testing, a reference cutoff of <500 U/mL is commonly used; thresholds around 1,000 U/mL are better framed as prognostic or risk-stratification cutoffs in selected studies, not as a diagnostic cutoff. Reported sensitivity of 70–90% and specificity of 85–95% vary by target disease and threshold and are not single-study values (Ishikawa N, et al. Respir Investig. 2012).
- In a meta-analysis of ILD, elevated KL-6 was associated with increased mortality risk (pooled HR = 2.05; 95% CI 1.50–2.78; Zhang T, et al. Front Immunol. 2021). This is a pooled estimate across ILD, not an IPF-specific effect size.
- During acute exacerbations, a further increase in KL-6 has been observed, potentially serving as an early detection marker.
Caveats
- KL-6 is not fully specific to IPF, as elevations are also seen in lung cancer, ARDS, and certain connective tissue diseases.
- Internationally, measurement kit standardization is limited, and use outside Japan has been restricted.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. SP-D (Surfactant Protein D)
Biological Background
SP-D is a secreted protein belonging to the collectin family, produced by type II alveolar epithelial cells and Clara cells. It plays a role in pathogen recognition and clearance in innate immunity, and also functions as a serum marker reflecting alveolar barrier integrity.
Clinical Data
- Serum SP-D levels in IPF patients are elevated approximately 2–3 fold compared to healthy controls, and correlate positively with the extent of honeycombing on HRCT.
- Correlation with the rate of FVC decline has been reported (Greene et al., Eur Respir J, 2002), making it useful for disease progression monitoring.
- Combined use with KL-6 improves diagnostic accuracy. In Japan, KL-6, SP-A, and SP-D are all insurance-covered clinical tests, although simultaneous billing is subject to restrictions.
Caveats
- Baseline values vary in smokers, so smoking history must be considered in interpretation.
- Mild elevations also occur in COPD and bronchial asthma, requiring attention in differential diagnosis.
3. MMP-7 (Matrix Metalloproteinase-7)
Biological Background
MMP-7 (matrilysin) is a matrix metalloproteinase secreted by alveolar epithelial cells and macrophages. It is involved in ECM (extracellular matrix) remodeling and promotes epithelial-mesenchymal transition (EMT) through E-cadherin cleavage and osteopontin activation.
Clinical Data
- In a large-scale study by Rosas et al. (PLoS Medicine, 2008), serum MMP-7 was shown to support diagnostic discrimination and disease-severity assessment (correlation with FVC% and DLCO%); later studies evaluated its prognostic and progression-prediction value (Richards 2012, Bauer 2017).
- IPF patients with elevated MMP-7 tend to have faster FVC decline and shorter survival.
- As a diagnostic marker, reasonable utility has been reported in differentiating IPF from subacute/chronic hypersensitivity pneumonitis.
- MMP-7 is also measured as an exploratory biomarker in clinical trials of nintedanib and pirfenidone covered in Latest Trends in IPF Treatment Drug Development.
Caveats
- MMP-7 is also expressed outside the lung (gastrointestinal epithelium, tumors), so specificity is somewhat limited.
- Standardized cutoff values have not yet been established.
4. CCL-18 (C-C Motif Chemokine Ligand 18)
Biological Background
CCL-18 (also known as PARC; Pulmonary and Activation-Regulated Chemokine) is a chemokine primarily secreted by alveolar macrophages. It reflects the activity of M2 (alternatively activated) macrophages and is known to stimulate collagen production by fibroblasts. For more on macrophage polarization, see our Macrophage Polarization article.
Clinical Data
- Prasse et al. (Am J Respir Crit Care Med, 2009) reported that IPF patients with serum CCL-18 > 150 ng/mL have significantly increased mortality risk (sensitivity 0.83, specificity 0.77). However, this is a research-cohort threshold, and inter-laboratory standardization of the ELISA is limited, so it should not be treated as a clinically implemented cutoff.
- CCL-18 also correlates with the rate of FVC decline and DLCO decline, gaining attention as a disease activity indicator.
- Prognostic utility has also been confirmed in systemic sclerosis-associated ILD (SSc-ILD), and it is an important marker for understanding the distinction between IPF and PPF progression.
Caveats
- Since no ortholog of CCL-18 exists in mice, direct measurement in preclinical models is difficult (discussed below).
Comparison of IPF Serum Biomarkers
| Item | KL-6 | SP-D | MMP-7 | CCL-18 |
|---|---|---|---|---|
| Source Cell | Type II alveolar epithelium | Type II alveolar epithelium / Clara cells | Alveolar epithelium / macrophages | Alveolar macrophages (M2) |
| Molecular Class | Mucin (MUC1) | Collectin | Metalloproteinase | CC chemokine |
| Primary Reflection | Alveolar epithelial injury/regeneration | Alveolar barrier breakdown | ECM remodeling | M2 macrophage activity |
| Assay Method | CLEIA / ECLIA | ELISA | ELISA / Luminex | ELISA |
| Clinical Cutoff | Reference <500 U/mL (Japanese clinical testing); ~1,000 U/mL used for prognostic stratification | Reference <110 ng/mL (Japanese clinical testing) | Being established | 150 ng/mL (research cohort) |
| Sensitivity / Specificity | 70–90% / 85–95% (diagnostic; varies by study) | Moderate | Moderate | 0.83 / 0.77 (mortality, Prasse 2009) |
| Japan Insurance Coverage | Yes | Yes | No (research use) | No (research use) |
| Prognostic Value | High (HR ≈ 2.05) | Moderate | High | High |
Biomarker Use in Clinical Trials
INBUILD Trial (Nintedanib)
The primary INBUILD result (slowing of FVC decline) in progressive fibrosing ILD was reported in NEJM 2019 (Flaherty KR, et al.). A separate circulating-biomarker analysis showed decreases in KL-6, SP-D, CA-125, and CA19-9 in the nintedanib group versus placebo, with the largest decrease in CA-125. Please also see Next-Generation Antifibrotic Drug Trends.
CAPACITY / ASCEND Trials (Pirfenidone)
A pooled post-hoc analysis of CAPACITY/ASCEND (Neighbors M, et al. Lancet Respir Med. 2018) evaluated plasma proteins such as CCL18 and MMP-7 as prognostic and predictive biomarkers (SP-D was not in the panel). Only CCL18 was consistently prognostic, while pirfenidone treatment benefit was consistent regardless of baseline biomarker concentration—no clear predictive or pharmacodynamic biomarker was identified.
These results suggest that no single biomarker has yet been established as a surrogate endpoint replacing FVC, while expectations for integrated evaluation via multi-marker panels are increasing.
Measurement in Preclinical Models: The Translational Perspective
In preclinical pulmonary fibrosis models—particularly the bleomycin model—these biomarkers are measured as adjunct indicators of drug efficacy.
Measurable Markers and Species Differences
- KL-6: The KL-6 epitope is restricted to humans and apes and is not expressed in wild-type mice, so direct serum/BAL measurement is not suitable in standard bleomycin models. It can be measured in specialized models such as human MUC1-expressing mice (Sakai M, et al. Biochem Biophys Res Commun. 2013). Standard preclinical candidates are better separated into SP-D, Mmp7, lung-tissue Muc1 expression, BAL albumin, and CCL2/Ym1/Ym2.
- SP-D: Mouse SP-D can be measured using commercial ELISA kits. Elevations are confirmed in BAL fluid and serum of bleomycin-treated mice.
- MMP-7: Mouse MMP-7 can be measured by ELISA or activity assays. Significant elevations have been reported in lung tissue and BAL fluid in the bleomycin model.
- CCL-18: No ortholog exists in mice, so direct measurement is not possible. Alternatives include CCL-2 (MCP-1) and Ym1/Ym2 as M2-related markers.
Recommended Experimental Design
- Simultaneous collection of BAL fluid and serum is recommended to compare local pulmonary and systemic changes.
- Combining with hydroxyproline (quantification of collagen deposition) and histopathology scores strengthens the biological interpretation of biomarker changes.
- Standardization of measurement timing (e.g., day 14 vs. day 21 post-injection) is important for human translation.
Conclusion
KL-6, SP-D, MMP-7, and CCL-18 are complementary biomarkers each reflecting different aspects of IPF pathogenesis (epithelial injury, barrier breakdown, ECM remodeling, macrophage activation). While each has limitations as a standalone marker, combining them as a panel is expected to enable higher-precision diagnosis, prognosis, and drug efficacy evaluation.
To successfully bridge preclinical-to-clinical translation, standardization of measurement methods in animal models and understanding of species differences are essential. As the IPF drug development pipeline expands, the importance of biomarker strategy will only continue to grow.
Related Articles
- Comprehensive Guide to Fibrosis Biomarkers (KL-6, SP-D, ELF Score)
- Latest Trends in IPF Treatment Drug Development 2025
- Outlook for Next-Generation Antifibrotic Drugs
- IPF vs PPF: Understanding the Progression Distinction
- Pitfalls of the Bleomycin Model
- Fundamentals of Macrophage Polarization
References
- Ishikawa N, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3–13. doi:10.1016/j.resinv.2012.02.001. PMID: 22554854
- Greene KE, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439–446. PMID: 11936520
- Rosas IO, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93. PMID: 18447576
- Prasse A, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717–723. PMID: 19179488
- Flaherty KR, et al. Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). N Engl J Med. 2019;381(18):1718–1727. PMID: 31566307
- Zhang T, et al. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2021;12:745233. PMID: 34956179
- Neighbors M, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone. Lancet Respir Med. 2018;6(8):615–626. PMID: 30072107
- Sakai M, et al. A novel lung injury animal model using KL-6-measurable human MUC1-expressing mice. Biochem Biophys Res Commun. 2013;432(3):460–465. PMID: 23410752